A RANDOMISED PHASE I PHARMACOKINETIC STUDY COMPARING HIGH-CONCENTRATION, LOW-VOLUME, AND CITRATE-FREE SB5 (40 MG/0.4 ML) WITH PRIOR SB5 FORMULATION, AND ADALIMUMAB BIOSIMILAR, IN HEALTHY MALE SUBJECTS

Authors
Category Primary study
JournalANNALS OF THE RHEUMATIC DISEASES
Year 2022
This article has no abstract
Epistemonikos ID: 887826fdfb32d862d5efca13f755e6b894061981
First added on: Feb 15, 2025